drugset / Trial / NCT00048932

A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis

NCT00048932

Phase 3 Completed 1795 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications.

Timeline

Start
2002-12
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Abatacept Other / unclassified 500 mg Intravenous
Comparator Abatacept Other / unclassified 750 mg Intravenous
Comparator Abatacept Other / unclassified 1000 mg Intravenous

Indications